Al-Nahrain Eye Clinics
Ramadi, Al-Anbar Governorate, 31001, Iraq
NCT Number: NCT06639711
The aim of the current intervention study is to determine the effectiveness of taurine containing eye drops (available under brand name VIZILOTON) to prevent the progression of grade I and II senile cataract.
This study could answer:
* Dose continuous use of taurine-containing eye drops could prevent further deterioration of vision in mild cases of cataract? * The acceptance/ compliance of participants to taurine-containing eye drops. * Could long-term use of taurine-containing eye drops cause adverse effect(s)?
Participants will:
* Take taurine-containing eye drops (VIZILOTON eye drops) 4 times a day for one year. * Visit eye clinic every 3 months for assessment and visual examination. * Keep notes for their symptoms and their adherence to treatment.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Interventional
Phase 1 / Phase 2
Ramadi, Al-Anbar Governorate, 31001, Iraq
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Taurine-containing eye drops (VIZILOTON) are applied 4 times daily for a period of one year
Other names: VIZILOTIN Eye Drops
Time frame: 1 Year
This study is active but is not currently recruiting participants.
Notify MeUniversity Of Anbar
Other
Taurine Affects the Progression of Senile Cataract: a Single-arm Pre-post Intervention Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05161520
Cataract, Eye Diseases
Guangzhou, Guangdong, China
View Trial DetailsNCT00594672
Age-Related Macular Degeneration, Cataract
Bethesda, Maryland, United States
View Trial DetailsNCT05317728
Cataract, Eye Diseases
San José, Costa Rica
View Trial DetailsNCT07741370
Age-related Cataract, Capsule Opacification
Hangzhou, Zhejiang, China
View Trial Details